Literature DB >> 1549623

Testosterone regulation of sex differences in fetal lung development.

H C Nielsen1.   

Abstract

Fetal lung development, in particular surfactant synthesis, exhibits a sexual dimorphism. Dihydrotestosterone (DHT) has been shown to delay fetal pulmonary surfactant production, but the potential role for testosterone is unknown. Both testosterone and DHT are potent masculinizing hormones, yet in some instances, an end organ specificity for DHT is present. We hypothesized that the delay in fetal lung surfactant production is dependent upon DHT such that inhibition of the synthesis of DHT from the precursor hormone testosterone would eliminate the sex difference by allowing the male fetus to produce surfactant at the female level. We tested this hypothesis using 17 beta-N,N-diethylcarbamoyl-4-aza-4-methyl-5-alpha-androstane-3-one (4-MA), a potent inhibitor of the enzyme 5 alpha-reductase, which converts testosterone into DHT. First, studies were performed in vivo. 4-MA (20 mg/kg/day) or an equivalent volume of vehicle was injected into pregnant rabbits from Day 12 through Day 26 of gestation. On Day 26, the fetuses were delivered, the lungs were lavaged, and fetal sex was noted. Treatment with 4-MA resulted in a lack of any male-female difference in the anogenital distance and no DHT was detected in the serum of any treated fetus. Phosphatidylcholine (PC), saturated phosphatidylcholine (SPC), and sphingomyelin (S) were measured in the lung lavage, and were expressed as the ratios of PC to sphingomyelin (PC:S) and SPC to sphingomyelin (SPC:S). Sex differences in the PC to sphingomyelin ratio of 4-MA-treated fetuses (female PC:S ratio, 1.43 +/- 0.14; male PC:S ratio, 1.00 +/- 0.13 [mean +/- SE]; P = 0.04) and in the SPC:S ratio of the 4-MA-treated group (female SPC:S ratio, 0.68 +/- 0.10; male SPC:S ratio, 0.35 +/- 0.10; P = 0.03) were present after treatment with 4-MA. The effect of testosterone and of 4-MA on fibroblast pneumonocyte factor (FPF) production was studied in vitro. Fetal rat lung fibroblasts were cultured to confluence with either no added androgen, DHT, testosterone, or testosterone plus 4-MA, and conditioned media for FPF were prepared. Conditioned media were added to fetal Type II cell cultures and FPF activity was measured as the degree of stimulation of the incorporation of [3H] choline into SPC. The conversion of radiolabeled testosterone to DHT by the fibroblasts was inhibited by 4-MA (10(-5) M). Conditioned media from untreated female fibroblasts stimulated with cortisol exhibited significant FPF activity ([3H]choline incorporation into SPC, 140 +/- 17% of control).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549623     DOI: 10.3181/00379727-199-43379

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  15 in total

1.  Impact of sex and ozone exposure on the course of pneumonia in wild type and SP-A (-/-) mice.

Authors:  Anatoly N Mikerov; Sanmei Hu; Faryal Durrani; Xiaozhuang Gan; Guirong Wang; Todd M Umstead; David S Phelps; Joanna Floros
Journal:  Microb Pathog       Date:  2012-01-20       Impact factor: 3.738

2.  Histopathologic evaluation of lung and extrapulmonary tissues show sex differences in Klebsiella pneumoniae - infected mice under different exposure conditions.

Authors:  Anatoly N Mikerov; Timothy K Cooper; Guirong Wang; Sanmei Hu; Todd M Umstead; David S Phelps; Joanna Floros
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-06

3.  The Lung Alveolar Cell (LAC) miRNome and Gene Expression Profile of the SP-A-KO Mice After Infection With and Without Rescue With Human Surfactant Protein-A2 (1A0).

Authors:  Nithyananda Thorenoor; Joanna Floros
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

4.  Hormonal basis for the gender difference in epidermal barrier formation in the fetal rat. Acceleration by estrogen and delay by testosterone.

Authors:  K Hanley; U Rassner; Y Jiang; D Vansomphone; D Crumrine; L Komüves; P M Elias; K R Feingold; M L Williams
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

5.  Sex-specific differences in neonatal hyperoxic lung injury.

Authors:  Krithika Lingappan; Weiwu Jiang; Lihua Wang; Bhagavatula Moorthy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464

6.  Establishment of the nasal microbiota in the first 18 months of life: Correlation with early-onset rhinitis and wheezing.

Authors:  Le Duc Huy Ta; Gaik Chin Yap; Carina Jing Xuan Tay; Alicia Shi Min Lim; Chiung-Hui Huang; Collins Wenhan Chu; Paola Florez De Sessions; Lynette P Shek; Anne Goh; Hugo P S Van Bever; Oon Hoe Teoh; Jian Yi Soh; Biju Thomas; Mahesh Babu Ramamurthy; Daniel Y T Goh; Christophe Lay; Shu-E Soh; Yiong Huak Chan; Seang-Mei Saw; Kenneth Kwek; Yap-Seng Chong; Keith M Godfrey; Martin Lloyd Hibberd; Bee Wah Lee
Journal:  J Allergy Clin Immunol       Date:  2018-02-13       Impact factor: 10.793

7.  Serum calcium values in term and late-preterm neonates receiving gentamicin.

Authors:  Arpitha Chiruvolu; William D Engle; Dorothy Sendelbach; M Denise Manning; Gregory L Jackson
Journal:  Pediatr Nephrol       Date:  2008-01-25       Impact factor: 3.714

Review 8.  The effects of smoking on the developing lung: insights from a biologic model for lung development, homeostasis, and repair.

Authors:  Virender K Rehan; Kamlesh Asotra; John S Torday
Journal:  Lung       Date:  2009-07-30       Impact factor: 2.584

9.  Actuarial survival of a large Canadian cohort of preterm infants.

Authors:  Huw P Jones; Stella Karuri; Catherine M G Cronin; Arne Ohlsson; Abraham Peliowski; Anne Synnes; Shoo K Lee
Journal:  BMC Pediatr       Date:  2005-11-09       Impact factor: 2.125

10.  Ablation of SP-A has a negative impact on the susceptibility of mice to Klebsiella pneumoniae infection after ozone exposure: sex differences.

Authors:  Anatoly N Mikerov; Rizwanul Haque; Xiaozhuang Gan; Xiaoxuan Guo; David S Phelps; Joanna Floros
Journal:  Respir Res       Date:  2008-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.